The N550K/H Mutations in FGFR2 Confer Differential Resistance to PD173074, Dovitinib, and Ponatinib ATP-Competitive Inhibitors

by Sara A Byron, Huaibin Chen, Andreas Wortmann, David Loch, Michael G Gartside, Farhad Dehkhoda, Steven P Blais, Thomas A Neubert, Moosa Mohammadi, Pamela M Pollock
Published 2013-08-01

Bcl‐2 inhibitors enhance FGFR inhibitor‐induced mitochondrial‐dependent cell death in FGFR2‐mutant endometrial cancer

by Leisl M. Packer, Samantha J. Stehbens, Vanessa F. Bonazzi, Jennifer H. Gunter, Robert J. Ju, Micheal Ward, Michael G. Gartside, Sara A. Byron, Pamela M. Pollock
Published 2019-04-01